Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers
- PMID: 25919761
- PMCID: PMC4406179
- DOI: 10.1186/s13058-014-0492-9
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers
Abstract
Introduction: More than 70 common alleles are known to be involved in breast cancer (BC) susceptibility, and several exhibit significant heterogeneity in their associations with different BC subtypes. Although there are differences in the association patterns between BRCA1 and BRCA2 mutation carriers and the general population for several loci, no study has comprehensively evaluated the associations of all known BC susceptibility alleles with risk of BC subtypes in BRCA1 and BRCA2 carriers.
Methods: We used data from 15,252 BRCA1 and 8,211 BRCA2 carriers to analyze the associations between approximately 200,000 genetic variants on the iCOGS array and risk of BC subtypes defined by estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and triple-negative- (TN) status; morphologic subtypes; histological grade; and nodal involvement.
Results: The estimated BC hazard ratios (HRs) for the 74 known BC alleles in BRCA1 carriers exhibited moderate correlations with the corresponding odds ratios from the general population. However, their associations with ER-positive BC in BRCA1 carriers were more consistent with the ER-positive associations in the general population (intraclass correlation (ICC) = 0.61, 95% confidence interval (CI): 0.45 to 0.74), and the same was true when considering ER-negative associations in both groups (ICC = 0.59, 95% CI: 0.42 to 0.72). Similarly, there was strong correlation between the ER-positive associations for BRCA1 and BRCA2 carriers (ICC = 0.67, 95% CI: 0.52 to 0.78), whereas ER-positive associations in any one of the groups were generally inconsistent with ER-negative associations in any of the others. After stratifying by ER status in mutation carriers, additional significant associations were observed. Several previously unreported variants exhibited associations at P <10(-6) in the analyses by PR status, HER2 status, TN phenotype, morphologic subtypes, histological grade and nodal involvement.
Conclusions: Differences in associations of common BC susceptibility alleles between BRCA1 and BRCA2 carriers and the general population are explained to a large extent by differences in the prevalence of ER-positive and ER-negative tumors. Estimates of the risks associated with these variants based on population-based studies are likely to be applicable to mutation carriers after taking ER status into account, which has implications for risk prediction.
Figures

References
-
- Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) Cancer Epidemiol Biomarkers Prev. 2012;21:134–47. doi: 10.1158/1055-9965.EPI-11-0775. - DOI - PMC - PubMed
-
- Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol. 2007;31:121–8. doi: 10.1097/01.pas.0000213351.49767.0f. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10 CA180868/CA/NCI NIH HHS/United States
- 11174/CRUK_/Cancer Research UK/United Kingdom
- C1287/A17523/CRUK_/Cancer Research UK/United Kingdom
- 1U19 CA148537/CA/NCI NIH HHS/United States
- C5047/A8384/CRUK_/Cancer Research UK/United Kingdom
- R01 CA083855/CA/NCI NIH HHS/United States
- U19 CA148537/CA/NCI NIH HHS/United States
- U10 CA037517/CA/NCI NIH HHS/United States
- C5047/A15007/CRUK_/Cancer Research UK/United Kingdom
- R01 CA102776/CA/NCI NIH HHS/United States
- U19 CA148065/CA/NCI NIH HHS/United States
- C1281/A12014/CRUK_/Cancer Research UK/United Kingdom
- CA116201/CA/NCI NIH HHS/United States
- UG1 CA189867/CA/NCI NIH HHS/United States
- R01 CA140323/CA/NCI NIH HHS/United States
- CA128978/CA/NCI NIH HHS/United States
- U24 CA114793/CA/NCI NIH HHS/United States
- RC4 CA153828/CA/NCI NIH HHS/United States
- U10 CA101165/CA/NCI NIH HHS/United States
- R01 CA142996/CA/NCI NIH HHS/United States
- C1287/A10710/CRUK_/Cancer Research UK/United Kingdom
- P50 CA125183/CA/NCI NIH HHS/United States
- UM1 CA164920/CA/NCI NIH HHS/United States
- P30 CA168524/CA/NCI NIH HHS/United States
- U01 CA161032/CA/NCI NIH HHS/United States
- C5047/A8385/CRUK_/Cancer Research UK/United Kingdom
- CA125183/CA/NCI NIH HHS/United States
- RC4CA153828/CA/NCI NIH HHS/United States
- CAPMC/ CIHR/Canada
- C1287/A16563/CRUK_/Cancer Research UK/United Kingdom
- N02-CP-11019-50/CP/NCI NIH HHS/United States
- C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
- CA 27469/CA/NCI NIH HHS/United States
- 5U01 CA113916/CA/NCI NIH HHS/United States
- U10 CA027469/CA/NCI NIH HHS/United States
- 1U19 CA148065/CA/NCI NIH HHS/United States
- C5047/A10692/CRUK_/Cancer Research UK/United Kingdom
- R01 CA128978/CA/NCI NIH HHS/United States
- N02 CP011019/CP/NCI NIH HHS/United States
- U10 CA180850/CA/NCI NIH HHS/United States
- N02 CP065504/CP/NCI NIH HHS/United States
- P50 CA116201/CA/NCI NIH HHS/United States
- CA 101165/CA/NCI NIH HHS/United States
- U01 CA113916/CA/NCI NIH HHS/United States
- 16563/CRUK_/Cancer Research UK/United Kingdom
- ImNIH/Intramural NIH HHS/United States
- 1U19 CA148112/CA/NCI NIH HHS/United States
- U19 CA148112/CA/NCI NIH HHS/United States
- R01 CA149429/CA/NCI NIH HHS/United States
- CA 37517/CA/NCI NIH HHS/United States
- 1U01 CA161032/CA/NCI NIH HHS/United States
- C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous